12 Covid-19 vaccines to watch

A range of Covid-19 vaccines are being developed worldwide. Which ones are authorised and assessed in the EU? Which are still in development? Check our table below.

Company	Type	Efficacy*	Doses	Storage	Status in Europe*	Secured by EU
Pfizer / BioNTech 🇩🇪🇺🇸	mRNA*	95%	💉💉 (💉)	-25°C to -15°C	Authorised	2.4 bn
Moderna 🇺🇸	mRNA	94.1%	💉💉 (💉)	-20°C	Authorised	460 mn
AstraZeneca / Oxford 🇸🇪🇬🇧	Adenovirus-vectored technology*	60% – 82%	💉💉	Fridge	Authorised	400 mn
Johnson&Johnson / Janssen 🇧🇪🇺🇸	Adenovirus-vectored technology	67%	💉	Fridge	Authorised	400 mn
Novavax 🇸🇪🇺🇸	Protein	89.3%	💉💉	Fridge	Authorised	~200 mn
CVnCoV – CureVac AG 🇩🇪	mRNA	❔	💉💉	Fridge	Rolling review stopped	405 mn
Sputnik V – Gamaleya Research Institute 🇷🇺	Adenovirus-vectored technology	91.6%	💉💉	-18°C	Rolling review Emergency use in Hungary, BiH, Serbia, Montenegro
CoronaVac – Sinovac 🇨🇳	Inactivated virus	Lack of data	💉💉	Fridge	Rolling review Emergency use in Turkey
BBIBP-CorV – Sinopharm 🇨🇳	Inactivated virus	Lack of data	💉💉	Fridge	Emergency use in Hungary, Serbia
VLA2001 – Valneva 🇫🇷	Inactivated virus	❔	❔	Fridge	Authorised	~60 mn
Sanofi & GSK 🇫🇷 (x2 vaccines)	mRNA & protein	❔	❔	❔	Rolling review of Vidprevtyn (protein-based vaccine)	300 mn

• Efficacy: numbers vary in different sources
• mRNA: messenger RNA, part of the virus’ genetic code
• Adenovirus-vectored technology: genetically modified cold virus
• Status in Europe: overview of the situation in EU and in the candidates/potential candidates countries.

Sources: WHO, EMA, EC, Astrazeneca, Sanofi, JnJ, Novavax, SputnikVaccine, TheLancet, Nature & other.

Last update : 29 June 2022